Compare DFNS & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFNS | TXMD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 24.4M |
| IPO Year | N/A | 2012 |
| Metric | DFNS | TXMD |
|---|---|---|
| Price | $0.17 | $2.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.7M | 60.7K |
| Earning Date | 04-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $203.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.16 | $0.98 |
| 52 Week High | $2.68 | $2.95 |
| Indicator | DFNS | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 28.42 | 51.81 |
| Support Level | N/A | $1.90 |
| Resistance Level | $0.51 | $2.16 |
| Average True Range (ATR) | 0.03 | 0.16 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 6.06 | 45.16 |
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with tough customer relationships and solid order backlogs, often capacity-and resource-constrained and specialized areas such as drones and autonomous vehicles, counter-drone systems, main manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and ideas, and decentralized day-to-day operations, it aims to strengthen essential defense capabilities and build long-term value.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.